Coronavirus (COVID-19)
Nearly Half of Public Wants to Get a COVID-19 Vaccine as Soon as They Can or Has Already Been Vaccinated, Up Since December
Latest from Kaiser Health News
-
Encuesta: casi la mitad de los adultos ahora quiere vacunarse contra covid lo antes posible
-
Lost on the Frontline: Explore the Database
-
If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine?
-
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers
COVID-19 Vaccine Monitor Dashboard
Latest PollingState Data and Policy Actions to Address Coronavirus
There have been over 3 million cases and 131,000 deaths due to COVID-19 in the U.S. Every state and Washington D.C. have eased or lifted at least one social distancing requirement — including 39 states that have eased or lifted stay-at-home orders.
COVID-19 Coronavirus Tracker
This tracker provides the number of cases and deaths from novel coronavirus by country, the trend in case and death counts by country, and a global map of showing which countries have cases and deaths. There have been over 11.8 million confirmed cases and 544,000 confirmed deaths worldwide.
Medicaid Emergency Authority Tracker: Approved State Actions to Address COVID-19
39 states are now addressing the coronavirus emergency with Medicaid/CHIP Disaster Relief State Plan Amendments (SPAs). This tracker also includes details on Section 1135 waivers and 1915 (c) Waiver Appendix K strategies and is regularly updated.
COVID-19 and Related State Data
Use this tool to create custom reports of COVID-19 and related state data. Group COVID-19 cases and deaths with indicators like total hospital beds, health insurance coverage and unemployment claims.
-
Who Didn’t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines
As the U.S. prepares for nationwide distribution of vaccines to combat COVID-19, some are asking whether people who get the first of two doses will return to complete the series. This analysis draws on Medicare Part D prescription drug claims data for the herpes zoster vaccine Shingrix, which also requires two doses, to shed light on this potential challenge of the leading COVID-19 vaccine candidates.
-
KFF COVID-19 Vaccine Monitor: December 2020
This initial survey for the KFF COVID-19 Vaccine Monitor tracks the public’s attitudes and experiences with COVID-19 vaccinations, with a focus on sub-groups of Americans. It explores confidence in vaccines, assesses trust in messengers, and highlights key challenges for vaccination efforts.
-
Gaps in Cost Sharing Protections for COVID-19 Testing and Treatment Could Spark Public Concerns About COVID-19 Vaccine Costs
In the issue brief, KFF experts highlight the laws and regulations that are in place to ensure access to free COVID-19 vaccines for individuals regardless of their insurance status and explain how vaccine administration costs will be covered in private insurance, Medicare and Medicaid, and for the uninsured.
-
Addressing Racial Equity in Vaccine Distribution
This brief provides an overview of barriers to vaccination that disproportionately affect people of color and discusses how current national recommendations and state vaccine allocation plans address racial equity.
COVID-19 Risks and Impacts Among Health Care Workers by Race/Ethnicity
This analysis provides insight into COVID-19 risks and impacts among health care workers and how they vary by race and ethnicity.
COVID-19 Racial Disparities in Testing, Infection, Hospitalization, and Death: Analysis of Epic Patient Data
This analysis builds on a continually growing body of research on racial disparities in COVID-19 by examining testing, infection, hospitalization, and death by race and ethnicity among patients in the Epic health record system.
Low-Income and Communities of Color at Higher Risk of Serious Illness if Infected with Coronavirus
This date note examines the share of non-elderly adults at higher risk of serious illness if infected with coronavirus by race/ethnicity and household income in 2018.
At-Home SARS-CoV-2 Testing: What Are the Options?
This interactive table includes vendors selling at-home SARS-CoV-2 diagnostic tests that have received emergency use authorization (EUA) from the Food and Drug Administration (FDA).
Five Things to Know about the Cost of COVID-19 Testing and Treatment
This brief answer key questions on affordability of COVID-19 testing and treatment for people who are uninsured and those insured through private coverage, Medicare, and Medicaid.
FAQs on Medicare Coverage and Costs Related to COVID-19 Testing and Treatment
These FAQs provide the latest guidance on testing and treatment related to COVID-19 for Medicare beneficiaries.
Key Questions About the New Medicaid Eligibility Pathway for Uninsured Coronavirus Testing
This issue brief answers key questions about how the new eligibility pathway is being implemented, drawing on frequently asked questions issued by the Centers for Medicare and Medicaid Services.